A Phase 1, Placebo-controlled, Randomized, Subject- And Investigator-blind, Sponsor-open, Crossover Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06266047 After Administration Of Single Ascending Doses To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2016
At a glance
- Drugs PF 6266047 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Pfizer
- 31 May 2016 Status changed from recruiting to completed.
- 03 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016, according to ClinicalTrials.gov record.
- 03 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016, according to ClinicalTrials.gov record.